Stent placement in patients with coronary heart disease decreases plasma levels of the endogenous nitric oxide synthase inhibitor ADMA
Stent placement in patients with coronary heart disease decreases plasma levels of the endogenous nitric oxide synthase inhibitor ADMA
复制标题
DOI：
10.3892/ijmm_00000176
复制
发表时间：
2009-05-01
影响因子：
5.4
通讯作者：
Bode-Boeger, Stefanie M.
中科院分区：
文献类型：
--
作者：
Ajtay, Zeno;Scalera, Fortunato;Bode-Boeger, Stefanie M.
不对称二甲基精氨酸（ADMA）是一种内源性一氧化氮合酶抑制剂，在冠心病（CHD）患者中浓度升高。经皮冠状动脉介入治疗（PCI）合并支架置入对冠心病患者血浆ADMA水平的潜在影响尚未研究。测定30例冠心病患者PCI术前24 h、置入裸金属支架或药物洗脱支架后1 h、5 d、30 d血浆中ADMA、l -精氨酸、对称二甲基精氨酸（SDMA）和l -鸟氨酸的浓度（支架组），以及20例单纯行血管造影的非冠心病患者血浆中ADMA、l -精氨酸、SDMA和l -鸟氨酸的浓度（对照组）。重复测量方差分析显示，ADMA组间相互作用的显著时间(F=12.8, p
The concentration of asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase, is increased in patients with coronary heart disease (CHD). The potential effect of percutaneous coronary intervention (PCI) with stent placement on ADMA plasma level in CHD patients has not yet been investigated. Concentrations of ADMA, L-arginine, symmetric dimethylarginine (SDMA), and L-ornithine were measured in the plasma of 30 CHD patients 24 h before, and 1 h, 5 days, and 30 days following PCI with bare-metal stent or drug-eluting stent placement (stent group) and in the plasma of 20 patients without CHD who underwent angiography alone (control group). A repeated measures ANOVA revealed the significant time by group interaction for ADMA (F=12.8, p